Kornimate/medical-research-clean huggingface dataset:
panorama observational study

Conditions: Arrhythmia; Sinus Node Disease; Heart Failure; Heart Block

Summary: to construct a computerized database of national profiles and epidemiological data on patients wearing medtronic implantable pacemakers and cardioverter defibrillators (both with or without cardiac resynchronization therapy), implantable loop recorders and leads used within their intended use. clinical variables will be analyzed in relation to device-based data and diagnostics.

panorama will collect a large database of device behavior, for instance to monitor long term behavior of device features, technical reliability and longevity, as well as to allow studying device performance in different subgroups of patients. larger databases are often essential for formulating and testing study hypotheses for prospective (randomized) trials. while it may depend on specific objectives for individual devices, reliable assessment of device performance over longer periods and in broad patient populations typically requires a study population from a few hundred to a few thousand patients. panorama collects acute and chronic patient and device data in a large population during routine usage of the device, without specific study interventions, and always within the approved intended use of the device. in the past, observational studies were designed and conducted specifically on a device-by-device case. panorama avoids the redesign of the same set of data. it establishes a core database which can be expanded with substudies creating more detailed data sets for particular crdm devices/features. panorama will be open for inclusion to any patient (to be) implanted with a crdm device. it shall be suitable for current and upcoming crdm devices implanted in patients. it will serve as an epidemiological tool designed to stratify morbidity and mortality of all cardiac diseases treated by implantable crdm devices.

Eligibility criteria:
inclusion criteria: * (to be) implanted with a medtronic market-released cardiac device, * signed patient data release form. exclusion criteria: * unwillingness or inability to cooperate or give voluntary consent

Keywords: bradyarrhythmia atrial fibrillation ventricular tachycardia ventricular fibrillation heart failure pacemaker implantable cardioverter defibrillator cardiac resynchronization therapy loop recorder registry
prognostic study of prostate cancer via dynamic change of psa in peritoneal drainage fluid after radical prostatectomy

Conditions: Prostatic Neoplasms; Prostate-Specific Antigen

Summary: this study investigates the prognostic value of dynamic changes in prostate-specific antigen (psa) levels found in the peritoneal drainage fluid after radical prostatectomy. prostate cancer is one of the most common cancers in men, and radical prostatectomy is a standard treatment. while psa levels in the blood are commonly used as a marker for diagnosis, this study focuses on the significance of psa levels in the prognosis of prostate cancer. the findings may provide insights into improved post-surgical monitoring and more tailored therapeutic strategies for prostate cancer patients.

this study examines the prognostic significance of prostate-specific antigen (psa) levels in the peritoneal drainage fluid following radical prostatectomy, a common surgical treatment for prostate cancer. psa is widely used as a biomarker for prostate cancer diagnosis, treatment response, and recurrence monitoring in the blood. however, this research seeks to explore the prognostic value of psa in the drainage fluid. the study involves continuous monitoring of psa levels in the drainage fluid after radical prostatectomy, with the hypothesis that dynamic changes in these levels could serve as an early warning system for potential tumor recurrence, residual disease, or metastasis. the research will correlate these fluid psa levels with patient outcomes, recurrence rates, and other clinical factors to determine their predictive value. by investigating this novel source of psa monitoring, the study aims to reduce invasive tests, enhance post-operative surveillance, and improve early detection of disease recurrence for prostate cancer patients. this research could contribute to refining post-surgical care protocols, offering a new tool for predict long-term outcomes for individuals undergoing radical prostatectomy.

Eligibility criteria:
inclusion criteria: * prostate cancer patients treated with radical prostatectomy exclusion criteria: * 1. received neoadjuvant endocrine/chemotherapy before surgery; * 2. urine leakage after surgery (positive creatinine test of drainage fluid).
effect of peep titration on the eelv measured by the nitrogen dilution technique in ards

Conditions: Acute Respiratory Distress Syndrome

Summary: mechanical ventilation of the patient with acute respiratory distress syndrome is one of the first therapies.

the application of positive end expiratory pressure is recommended but the question remains "how to set the best positive end-expiratory pressure (peep) level for each patient? ". different titration techniques have been studied on oxygenation and respiratory mechanics parameters without reaching a consensus. currently we have a module that is connected to the ventilator to collect the patient's lung volume. it will therefore allow us to optimize the settings of the ventilator and to set the best level of positive end-expiratory pressure "best peep" in order to individualize our treatment for each patient.

Eligibility criteria:
inclusion criteria: * patients admitted to intensive care with a diagnosis of moderate to severe ards in accordance with the berlin criteria, i.e. a pafi \ 5cm h20 ratio * diagnosis of ards made within 72 hours * age over 18 years * informed consent of the patient and/or trusted person where applicable exclusion criteria: * start of mechanical ventilation more than 72 hours prior to inclusion. * sdra evolving for more than 72 hours * presence of major hemodynamic instability with mean blood pressure \ 150bpm with an increase in vasopressor amine dosage of more than 20% over the last 6 hours. * intracranial hypertension with cpp\<60mmhg * massive hemoptysis requiring immediate surgical or interventional radiology procedure * tracheal surgery (except intensive care tracheotomy) or sternotomy within the previous 15 days * trauma or surgery of the face in the previous 15 days. * deep vein thrombosis treated for less than 2 days * pacemaker implantation in the last 2 days * unstable fracture (spine, femur or pelvis) * respiratory reasons * use of extracorporeal oxygenation * nitric oxide * pleural drainage system with bronchopleural gap * pulmonary transplantation * poor respiratory tolerance per procedure with desaturation spo2\<85%. * poor hemodynamic tolerability per procedure combining hypotension with map\<65mmhg and a 20% increase in norepinephrine dosage. * lack of patient consent to proceed * minor patient * lack of consent

Keywords: respiratory distress titration end-expiratory
group treatment for hoarding disorder

Conditions: Hoarding Disorder

Summary: this study assesses the effectiveness of a novel group treatment for hoarding disorder.

the primary aim of this study is to investigate the effectiveness of a novel group treatment for hoarding disorder. participants will be randomized to receive either treatment as usual (cognitive behavioral therapy: cbt) or treatment as usual augmented by interpersonal psychotherapy (ipt). it is hypothesized that group cbt with ipt will result in greater decreases in hoarding symptoms, as compared to standard group cbt. it is further hypothesized that cbt with ipt will result in greater reductions in object attachment and maladaptive beliefs about relationships with others, as well as greater increases in interpersonal attachment.

Eligibility criteria:
inclusion criteria: -clinical diagnosis of hd exclusion criteria: * evidence of a severe mental illness or substance use disorder that would impede the completion of the treatment * current receipt of cbt for hd * initiation of new psychotropic medications for symptoms of hd
deferiprone for the prevention of contrast-induced acute kidney injury

Conditions: Contrast-Induced Acute Kidney Injury

Summary: the primary objective of this trial is to assess the impact of crmd-001 on markers of contrast-induced acute kidney injury (aki) in high-risk patients with chronic kidney disease (ckd) undergoing coronary angiography and pci.

this trial will evaluate whether treatment with crmd-001 (unique formulations of the iron chelator, deferiprone) will reduce the incidence of aki in subjects with ckd and additional risk factors. adult subjects with moderate to severe ckd who are undergoing coronary angiography and pci will be randomized to either placebo or crmd-001 and followed for 90 days. subjects will receive 8 days of randomized therapy starting 1-3 hours prior to angiography. the primary endpoint of the trial will be the difference in mean paired change of a panel of sensitive renal biomarkers between the groups. differences in renal or cardiovascular clinical events will also be evaluated.

Eligibility criteria:
inclusion criteria: 1. age 18 or older 2. egfr of \< 60 ml/min/1.73 m2 3. presence of at least one additional risk factor: * diabetes mellitus * age ≥ 75 years * left ventricular ejection fraction ≤ 40% exclusion criteria: 1. end-stage renal disease 2. recent change in serum creatinine 3. primary pci for stemi 4. currently receiving mechanical ventilation 5. severe heart failure of cardiogenic shock 6. requirement for inotropic support (prior 30 days) 7. sustained hypertension \> or = 200/110 8. subject not expected to live for 90 days 9. anticipated use of ioxaglate or iohexol 10. currently receiving fenoldopam, dopamine, theophylline, aminophylline, mannitol, n-acetyl cysteine or ascorbic acid 11. absolute neutrophil count \< 1500 12. hemoglobin \< 8 gm/dl

Keywords: acute kidney injury contrast-induced nephropathy labile iron iron chelation deferiprone
furosemide pharmacodynamics and pharmacokinetics after subcutaneous or oral administration

Conditions: Heart Failure

Summary: the purpose of this pilot study is to investigate the pharmacodynamic and pharmacokinetic parameters of a novel furosemide formulation administered subcutaneously as compared to oral furosemide.


Eligibility criteria:
inclusion criteria: * written informed consent obtained before any assessment is performed * male and female subjects ≥18 years of age, with body weight \<120 kg and body mass index (bmi) \<30 kg/m2 * female subjects must be at least 2 years post-menopausal * participant must have been on oral furosemide (40 mg oid or bid) or therapeutic equivalent (bumetanide 1 mg oid or bid) for a period 90 days before the first dose of study medication * history of chronic heart failure according to 2012 esc guidelines with presence of moderate symptoms of chronic fluid overload. chronic fluid overload is defined as presence of stable signs and symptoms of heart failure and congestion, like dyspnea at mild exertion or minimal exertion, pulmonary congestion and/or peripheral edema at the time of presentation in combination with elevated levels on natriuretic peptides (nt-probnp \> 300 ng/l) * in the opinion of the investigator, able to participate in the study exclusion criteria: * acute decompensated heart failure (adhf) or recent history of adhf or significant worsening in their hf symptoms (within prior 2 weeks) * contraindication to furosemide * systolic bp (sbp) \< 90 mm hg * temperature \> 38°c (oral or equivalent) or sepsis or active infection requiring i.v. anti-microbial treatment * serum sodium \< 130 mmol/l and serum potassium \< 3.0 mmol/l * current or planned (throughout the completion of study drug infusion) treatment with any i.v. therapies, including inotropic agents, vasopressors, levosimendan, nesiritide or analogues; or mechanical support (intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device) * history of gastric or intestinal surgery that may affect absorption of oral medication * presence or need for urinary catheterization * current or planned ultrafiltration, hemofiltration, or dialysis * impaired renal function defined as an estimated glomerular filtration rate (egfr) on admission \< 30 ml/min/1.73 m2 will be calculated as per standard at local laboratory * administration of intravenous radiographic contrast agent within 72 hours prior to screening or acute contrast-induced nephropathy at the time of screening * major surgery within 30 days prior to screening * administration of an investigational drug or implantation of investigational device, or participation in another trial, within 30 days before screening * inability to follow instructions or comply with procedures * any surgical or medical condition which in the opinion of the investigator may interfere with participation in the study or which may affect the outcome of the study

Keywords: chronic fluid overload
hydroxypropyl-methylcellulose and glicopro® eyedrops in the treatment of dry eye disease: clinical study

Conditions: Dry Eye

Summary: the goal of this clinical trial is to learn if hydroxypropyl-methylcellulose and glicopro® eyedrops work to treat mild-to-moderate dry eye disease in adult patients. the main questions it aims to answer are: do hydroxypropyl-methylcellulose and glicopro® eyedrops reduce patients' symptoms? do hydroxypropyl-methylcellulose and glicopro® eyedrops increase patients' tear film stability? researchers will compare hydroxypropyl-methylcellulose and glicopro® eyedrops to hydroxypropyl-methylcellulose without glicopro® eyedrops to see if hydroxypropyl-methylcellulose and glicopro® formulation works better to treat dry eye.. participants will * take hydroxypropyl-methylcellulose and glicopro® eyedrops or hydroxypropyl-methylcellulose eyedrops every day for 3 months * visit the clinic 3 times in 3 months for checkups and tests


Eligibility criteria:
inclusion criteria: * age \>18 years * ocular surface disease index (osdi) \>12 and \<65 * fluorescein breakup time (fbut) \ 1 and \<4). exclusion criteria: * systemic or ocular diseases with known effect on tear film and ocular surface * systemic or ocular medications with known effect on tear film and ocular surface * contact lens wearing, * ocular surgery in the 12 months before enrollment * known allergy or poor tolerance to any ingredient of the study products * presumed poor compliance to study procedures.

Keywords: dry eye disease glicopro® hydroxypropyl-methylcellulose
efficacy of hellencare in early-stage alzheimer's disease

Conditions: Alzheimer's Disease Dementia

Summary: the goal of this clinical trial is to evaluate whether hellencare, a multicomponent nutraceutical, improves cognitive and functional outcomes in patients with early-stage alzheimer's disease (ad). the investigators will compare changes in outcomes between the hellencare group and the placebo group to determine if the intervention is effective and safe.


Eligibility criteria:
inclusion criteria: * participants aged 50 to 85 years * clinically diagnosed for the first time with probable alzheimer's disease dementia (ad dementia) or ad-related mild cognitive impairment (mci) according to the national institute on aging-alzheimer's association (nia-aa) core clinical criteria. * mmse (mini-mental state examination): score between 22 and 30. * cdr (clinical dementia rating): total score of 0.5 or 1. memory domain score on cdr: ≥0.5. * able to comply with study procedures and attend scheduled visits. * willingness to participate and provide informed consent. exclusion criteria: * presence of other dementia-causing conditions (e.g., vascular dementia, lewy body dementia, etc) * severe neurological comorbidities (e.g., history of seizures, cerebral infarction, intracerebral hemorrhage, traumatic brain injury, brain tumors, etc.) * presence of severe anxiety, depression, schizophrenia, bipolar disorder, or other psychotic disorders requiring active treatment. * history of alcohol or drug dependence within the past 1 year. * allergies to study dietary supplement. * use of anti-dementia medications ( e.g., donepezil, galantamine, memantine, etc).
halitosis during active orthodontic treatment

Conditions: Halitosis

Summary: to determine the effect of different cleaning methods and devices in reducing halitosis during active orthodontic treatment.

. observer - blind clinical trial, randomly divided into four groups, a, b, c and d. each group will undergo clinical evaluation and oral malodor assessment and they will be assigned electric or manual toothbrushes with super floss or water floss respectively.clinical evaluation will include plaque index (pi), gingival bleeding index (gbi), bracket index.and halitosis will be measured by halimeter . measurements and time frame: initial measurements (t0), after two weeks (t1), and after four weeks (t2) ( according to previous studies that uses the same period of time for measurements),17, 18 plaque index (pi), gingival bleeding index (gbi), bracket index and halimeter reading . during the first week after the start of the study (t0)

Eligibility criteria:
inclusion criteria: 1. participants with fixed orthodontic appliance. 2. participants age 14 years and above and didn't have mental of physical disabilities. 3. participants willing to comply with given oral hygiene instructions. exclusion criteria: 1. patients with mental retardation. 2. patients with systematic diseases.
inflammatory effect comparison between fentanyl and remifentanil in mastectomy under general anesthesia

Conditions: Breast Disease; Anesthesia; Inflammatory Response

Summary: mastectomy triggers stress and inflammation responses due to tissue trauma. surgical stress will increase levels of hormones (adrenocorticotropic hormone, cortisol, antidiuretic hormone, epinephrine, norepinephrine, and dopamine) and inflammatory cytokines (tumor necrotic factor-α, interleukin-1, interleukin-2, and interleukin-6) in the body. this causes insulin resistance, gluconeogenesis, and glycolysis, and impaired insulin secretion, which results in hyperglycemia due to intraoperative stress. intraoperative hyperglycemia increases postoperative complications and mortality. inhibition of hyperglycemia due to operative stress and stress hormones with good anesthetic management in improving patient outcomes. the choice of opioid type plays an important role in suppressing the perioperative stress and inflammatory response. opioids are an alternative, besides the use of regional anesthetic techniques which have been proven to suppress the perioperative stress response. fentanyl is one of the phenylpiperidine synthetic opioids. large doses of fentanyl can reduce stress responses but also increase side effects, such as hemodynamic instability and decrease t-cell function. remifentanil provides unique pharmacokinetic benefits through nonspecific esterase enzyme metabolism, so it has a very fast onset and half-life. in addition, remifentanil also provides benefits in reducing the production of interleukin 6 cytokines (il-6) and tumor necrosis factor α (tnf-α) and inhibits neutrophil migration through the endothelial layer. the stress response to stress and inflammation is directly proportional to the dose of remifentanil given. it is reported that remifentanil can suppress cortisol response according to increasing dose. winterhalter et al. and lee et al. reported that remifentanil is better at suppressing the stress response than fentanyl. on the other hand, bell et al. showed no difference in cortisol and hemodynamic levels between the two groups. the goal of this study is to see if remifentanil provides less increase in serum epinephrine level, norepinephrine level, platelet to lymphocyte ratio (plr), lymphocyte to monocyte ratio (lmr), and blood glucose level at one-hour and 24-hours postoperative in patients undergoing mastectomy surgery under general anesthesia.


Eligibility criteria:
inclusion criteria: * patients scheduled for a mastectomy under general anesthesia * patients aged 30-65 years old * asa physical status: i-ii exclusion criteria: * refusal to be included in the study * history of opioid allergies * long-term use of steroids * patients on β blockers medication * history of diabetes, autoimmune disease, or heart disease
bronchiolitis: evaluation of wang's score as a predictor of the duration of oxygen therapy in bronchiolitis

Conditions: Bronchiolitis

Summary: evaluation of wang's score as a predictor of the duration of oxygen therapy in bronchiolitis

bronchiolitis is a viral disease of very variable evolution going from a simple outpatient treatment to the necessity of hospitalization in intensive care. this epidemic disease is found all year round with a seasonal peak from mid-october to late winter. the risk factors for progression to severe or prolonged bronchiolitis have been highlighted, but the duration of hospitalization is difficult to predict, which leads to organizational difficulties in the services and additional anxiety for the families. the management of beds during winter epidemics can be a source of difficulties for hospitalization services, with the need to temporarily increase reception places or transfer children to other hospitals. oxygen rescue is the main factor limiting the discharge of the pediatric ward. this criterion seems to us more suitable than the total duration of hospitalization. indeed, other factors such as the family environment or food difficulties can delay the child's departure from the service. their assessment seems to be more subjective, their assessment may vary from one doctor to another. better management of beds during winter epidemics could help to avoid changes in service during hospitalization, thus facilitating relationships between caregivers and families.

Eligibility criteria:
inclusion criteria: * infants under 2 years * infants consulting at the emergency department of the university hospital of rennes for a first or second episode of bronchiolitis with criteria for hospitalization exclusion criteria: * children transferred from another department such as pediatric intensive care unit * children for whom wang's score could not be established * child over 2 years old at diagnosis * child with a 3rd episode of bronchiolitis or more.
regional anesthesia for percutaneous transluminal angioplasty

Conditions: Peripheral Artery Occlusive Disease; Percutaneous Transluminal Angioplasty

Summary: in this study, the effects of regional anesthesia method applied in patients who will undergo percutaneous transluminal angioplasty for lower extremity revascularization will be investigated comparatively.


Eligibility criteria:
inclusion criteria: * age: \> 18 years * peripheral artery occlusive disease * eligibility for pta exclusion criteria: * patients' refusal * under the age of 18 * language problems (not knowing turkish) * psychological or mental disorders. * disturbance of conscious level. * uncooperative patients * those who are allergic to anesthetic drugs to be used * those with contraindications for the application of peripheral nerve block (coagulopathy, skin infection at the block site) * need for endotracheal intubation or general anesthesia

Keywords: percutaneous transluminal angioplasty tissue oxygenation